AAAAAA
Results:
1-17
|
Results: 17
Authors:
Saves, M
Morlat, P
Chene, G
Peuchant, E
Pellegrin, I
Bonnet, F
Bernard, N
Lacoste, D
Salamon, R
Beylot, J
Citation: M. Saves et al., Prognostic value of plasma markers of immune activation in patients with advanced HIV disease treated by combination antiretroviral therapy, CLIN IMMUNO, 99(3), 2001, pp. 347-352
Authors:
Pellegrin, I
Garrigue, I
Caumont, A
Pellegrin, JL
Merel, P
Schrive, MH
Bonot, P
Fleury, H
Citation: I. Pellegrin et al., Persistence of zidovudine-resistance mutations in HIV-1 isolates from patients removed from zidovudine therapy for at least 3 years and switched to astavudine-containing regimen, AIDS, 15(8), 2001, pp. 1071-1073
Authors:
Ngo-Giang-Huong, N
Deveau, C
Da Silva, I
Pellegrin, I
Venet, A
Harzic, M
Sinet, M
Delfraissy, JF
Meyer, L
Goujard, C
Rouzioux, C
Citation: N. Ngo-giang-huong et al., Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy, AIDS, 15(6), 2001, pp. 665-673
Authors:
Viallard, JF
Pellegrin, I
Mercie, P
Moreau, JF
Pellegrin, JL
Citation: Jf. Viallard et al., Infectious mononucleosis, REV MED IN, 22, 2001, pp. 299S-300S
Authors:
Merel, P
Pellegrin, I
Garrigue, I
Caumont, A
Schrive, MH
Birac, V
Bonot, P
Fleury, H
Citation: P. Merel et al., Comparison of capillary electrophoresis sequencing with the new CEQ 2000 DNA Analysis System to conventional gel based systems for HIV drug resistance analysis, J VIROL MET, 98(1), 2001, pp. 9-16
Authors:
Pellegrin, I
Breilh, D
Birac, V
Deneyrolles, M
Mercie, P
Trylesinski, A
Neau, D
Saux, MC
Fleury, HJA
Pellegrin, JL
Citation: I. Pellegrin et al., Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens, THER DRUG M, 23(4), 2001, pp. 332-340
Authors:
Pellegrin, I
Segondy, M
Garrigue, I
Izopet, J
Montes, B
Pellegrin, JL
Reynes, J
Massip, P
Puel, J
Fleury, H
Citation: I. Pellegrin et al., Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy, J ACQ IMM D, 25(5), 2000, pp. 465-466
Authors:
Morlat, P
Marimoutou, C
Dequae-Merchadou, L
Pellegrin, I
Mercie, I
Neau, D
Beylot, J
Dabis, F
Citation: P. Morlat et al., Dual nucleoside regimens in nonadvanced HIV infection: Prospective follow-up of 130 patients, Aquitaine Cohort, 1996 to 1998, J ACQ IMM D, 23(3), 2000, pp. 255-260
Authors:
Burgard, M
Izopet, J
Dumon, B
Tamalet, C
Descamps, D
Ruffault, A
Vabret, A
Bargues, G
Mouroux, M
Pellegrin, I
Ivanoff, S
Guisthau, O
Calvez, V
Seigneurin, JM
Rouzioux, C
Citation: M. Burgard et al., HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment, AIDS RES H, 16(18), 2000, pp. 1939-1947
Authors:
Garrigue, I
Pellegrin, I
Hoen, B
Dumon, B
Harzic, M
Schrive, MH
Sereni, D
Fleury, H
Citation: I. Garrigue et al., Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA, AIDS, 14(18), 2000, pp. 2851-2855
New molecular assays to predict occurrence of cytomegalovirus disease in renal transplant recipients
Authors:
Pellegrin, I
Garrigue, I
Ekouevi, D
Couzi, L
Merville, P
Merel, P
Chene, G
Schrive, MH
Trimoulet, P
Lafon, ME
Fleury, H
Citation: I. Pellegrin et al., New molecular assays to predict occurrence of cytomegalovirus disease in renal transplant recipients, J INFEC DIS, 182(1), 2000, pp. 36-42
Authors:
Reynes, J
Denisi, R
Massip, P
Izopet, J
Pellegrin, I
Segondy, M
Citation: J. Reynes et al., Once-daily administration of didanosine in combination with stavudine in antiretroviral-naive patients, J ACQ IMM D, 22(1), 1999, pp. 103-105
Authors:
Molina, JM
Cheuc, G
Ferchal, F
Journot, V
Pellegrin, I
Sombardier, MN
Rancinan, C
Cotte, L
Madelaine, I
Debord, T
Decazes, JM
Citation: Jm. Molina et al., Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients, ANTIVIR TH, 4, 1999, pp. 71-74
Authors:
Pellegrin, I
Izopet, J
Reynes, J
Denayrolles, M
Montes, B
Pellegrin, JL
Massip, P
Puel, J
Fleury, H
Segondy, M
Citation: I. Pellegrin et al., Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plusdidanosine combination therapy, AIDS, 13(13), 1999, pp. 1705-1709
Authors:
Pellegrin, I
Garrigue, I
Binquet, C
Chene, G
Neau, D
Bonot, P
Bonnet, F
Fleury, W
Pellegrin, JL
Citation: I. Pellegrin et al., Evaluation of new quantitative assays for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency virus-positive patients, J CLIN MICR, 37(10), 1999, pp. 3124-3132
Authors:
Mercie, P
Devianne, I
Viallard, JF
Faure, I
Pellegrin, I
Leng, B
Dupon, M
Barbeau, P
Fleury, H
Pellegrin, JL
Citation: P. Mercie et al., Vascular endothelial growth factor (VEGF(165)) plasma level increase with immunodepression in AIDS patients with Kaposi's sarcoma, MICROVASC R, 57(2), 1999, pp. 208-210
Authors:
Molina, JM
Chene, G
Ferchal, F
Journot, V
Pellegrin, I
Sombardier, MN
Rancinan, C
Cotte, L
Madelaine, I
Debord, T
Decazes, JM
Citation: Jm. Molina et al., The ALBI trial: A randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus, J INFEC DIS, 180(2), 1999, pp. 351-358
Risultati:
1-17
|